Clinical Trial Update: Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing MYL-1701P to Eylea for diabetic macular edema completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• EYLEA (Aflibercept)
• MYL-1701P

Snippet

Sponsor: Mylan Pharmaceuticals Inc | Conditions: Diabetic Macular Edema | Phase 3 | Status: COMPLETED | Results posted: 2023-03-07